US OptionsDetailed Quotes
EMN240920C75000
- 12.60
- 0.000.00%
15min DelayTrading Feb 1 13:41 ET
0.00High0.00Low
0.00Open12.60Pre Close0 Volume3 Open Interest75.00Strike Price0.00Turnover53.74%IV-13.10%PremiumSep 20, 2024Expiry Date25.81Intrinsic Value100Multiplier24DDays to Expiry0.00Extrinsic Value100Contract SizeAmericanOptions Type0.9867Delta0.0024Gamma3.88Leverage Ratio-0.0197Theta0.0486Rho3.83Eff Leverage0.0088Vega
Eastman Chemical Stock Discussion
Sign in to post a comment
Eastman Chemical's statutory earnings may have been distorted by unusual items, suggesting that its true underlying earnings power could be less than its statutory profit. There are also 2 warning signs for Eastman Chemical that investors should be aware of.
EPS growth and falling share price mismatch suggests a shift in market perception of the company. Recent sell-off could be a long-term growth opportunity, but investors should heed 2 warning signs for Eastman Chemical.
A decline in earnings per share and ongoing risk to future dividends make Eastman Chemical less appealing for dividend-focused investors despite efforts to increase the dividend payout ratio.
1
Despite Eastman Chemical's fair trading price, future buying opportunities may arise from the stock's volatility. The company's bright outlook, propelled by a predicted profit doubling, might lead to increased cash flow and share valuation. However, a thorough balance sheet analysis is recommended before investing.
Analyst Jeffrey Zekauskas from J.P. Morgan predicts Eastman Chemical's earnings to rebound in 2024. Poor performance in 2023 due to market challenges, but possible recovery driven by dividends and good free cash flow expected.
Gapping up
In reaction to earnings/guidance:
• $Planet Labs PBC (PL.US)$ +11.3%, $Core & Main (CNM.US)$ +6.1%, $Regal Rexnord (RRX.US)$ +2% (reaffirms outlook), $Oracle (ORCL.US)$ +1.6%
Other news:
• $Akero Therapeutics (AKRO.US)$ +93.2% (reports Phase 2b HARMONY Study)
• $Akouos (AKUS.US)$ +10.3% (FDA clears IND application to initiate a Phase 1/2 first in human pediatric clinical trial of AK-OTOF)
• $Catalyst Pharmaceuticals (CPRX.US)$ +7.7...
In reaction to earnings/guidance:
• $Planet Labs PBC (PL.US)$ +11.3%, $Core & Main (CNM.US)$ +6.1%, $Regal Rexnord (RRX.US)$ +2% (reaffirms outlook), $Oracle (ORCL.US)$ +1.6%
Other news:
• $Akero Therapeutics (AKRO.US)$ +93.2% (reports Phase 2b HARMONY Study)
• $Akouos (AKUS.US)$ +10.3% (FDA clears IND application to initiate a Phase 1/2 first in human pediatric clinical trial of AK-OTOF)
• $Catalyst Pharmaceuticals (CPRX.US)$ +7.7...
10
GOLDMAN SACHS
• $Bausch + Lomb Corp. (BLCO.US)$ Goldman Sachs analyst Amit Hazan initiated coverage of Bausch + Lomb with a Neutral rating and $22 price target, implying 22% upside potential. The analyst sees Bausch + Lomb's current offering and pipeline as positioning it well to maintain or expand share in the "attractive and durable' eye care market.
• $Steel Dynamics (STLD.US)$ Goldman Sachs analyst Emily Chieng downgraded Steel Dynamics to Neutral...
• $Bausch + Lomb Corp. (BLCO.US)$ Goldman Sachs analyst Amit Hazan initiated coverage of Bausch + Lomb with a Neutral rating and $22 price target, implying 22% upside potential. The analyst sees Bausch + Lomb's current offering and pipeline as positioning it well to maintain or expand share in the "attractive and durable' eye care market.
• $Steel Dynamics (STLD.US)$ Goldman Sachs analyst Emily Chieng downgraded Steel Dynamics to Neutral...
21
Upgrades
• $Grab Holdings (GRAB.US)$: Bernstein Upgrades to Outperform from Market Perform - PT $3.04
• $Linde (LIN.US)$: Evercore ISI Upgrades to Outperform from In Line - PT $355
• $Magellan Midstream (MMP.US)$: Wells Fargo Upgrades to Overweight from EqualWeight - PT $56 (from $54)
• $Mercury Systems (MRCY.US)$: Baird Upgrades to Outperform from Neutral - PT $72 (from $56)
• $Nurix Therapeutics (NRIX.US)$: Wells Fargo Upgrades to Overweight from EqualWeight - PT...
• $Grab Holdings (GRAB.US)$: Bernstein Upgrades to Outperform from Market Perform - PT $3.04
• $Linde (LIN.US)$: Evercore ISI Upgrades to Outperform from In Line - PT $355
• $Magellan Midstream (MMP.US)$: Wells Fargo Upgrades to Overweight from EqualWeight - PT $56 (from $54)
• $Mercury Systems (MRCY.US)$: Baird Upgrades to Outperform from Neutral - PT $72 (from $56)
• $Nurix Therapeutics (NRIX.US)$: Wells Fargo Upgrades to Overweight from EqualWeight - PT...
16
3
![[undefined]](https://static.moomoo.com/nnq/emoji/static/image/default/default-black.png?imageMogr2/thumbnail/36x36 "undefined"){kind=small}
Gainers:
• $Checkmate Pharmaceuticals (CMPI.US)$ +331.5% (Regeneron Pharma (REGN) to acquire CMPI for $10.50/share in cash)
• $Axsome Therapeutics (AXSM.US)$ +27.9% (received and agreed to Postmarketing Requirements/Commitments proposed by the FDA with respect to the New Drug Application for its AXS-05 product candidate for the treatment of major depressive disorder)
• $Super Micro Computer (SMCI.US)$ +14.3% (earnings report)
• $Plug Power (PLUG.US)$ +9.24% (t...
• $Checkmate Pharmaceuticals (CMPI.US)$ +331.5% (Regeneron Pharma (REGN) to acquire CMPI for $10.50/share in cash)
• $Axsome Therapeutics (AXSM.US)$ +27.9% (received and agreed to Postmarketing Requirements/Commitments proposed by the FDA with respect to the New Drug Application for its AXS-05 product candidate for the treatment of major depressive disorder)
• $Super Micro Computer (SMCI.US)$ +14.3% (earnings report)
• $Plug Power (PLUG.US)$ +9.24% (t...
16
1
No comment yet
JACKmusk : Good buy